"I love Aeglea BioTherapeutics | Rare Metabolic Disease | Home"

2022-05-16 18:24:24

ContactPrivacy PolicyTerm of UsePurchase TermsCOVID-19 Statement CompanyAboutLeadershipPartneringContactFocusEnzyme TherapeuticsRare Metabolic DiseasePublicationsProgramsPipelinePegzilarginaseAGLE-177Research ProgramsClinical TrialsCareersJob OpeningsLife at AegleaInvestors & MediaCompany OverviewPress ReleasesEvents & PresentationsStock InformationStock Quote & ChartAnalyst CoverageFinancialsQuarterly ReportsAnnual Reports and ProxySEC FilingsCorporate GovernanceGovernance DocumentsManagementBoard of DirectorsCommittee CompositionResourcesInvestor FAQsInformation Request FormInvestor Email AlertsInvestor ContactsPatients & FamiliesOverviewArginase 1 DeficiencyHomocystinuriaDiet & NutritionClinical Trials FAQs Select Page DeliveringMetabolic Harmony.Transforming Life. Aeglea specializes in rare metabolic disorders, developing novel medicines to bring better balance to the lives of patients and families battling these devastating diseases. Learn More 3 Aeglea specializes in rare metabolic disorders, developing novel medicines to bring better balance to the lives of patients and families battling these devastating diseases.Learn More Engineering Solutions with Enzyme TherapeuticsBy engineering small changes in human enzymes, we aim to have a big impact on the lives of patients and their families. Learn More Engineering Solutions with Enzyme TherapeuticsBy engineering small changes in human enzymes, we aim to have a big impact on the lives of patients and their families. Learn More Developing Therapies for Rare Metabolic DiseaseWe take on diseases that are forgotten or overlooked by others because every patient deserves a chance at a better life. View Our Pipeline Latest News from Aeglea View All May 05, 2022 Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market May 05, 2022 Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates Apr 12, 2022 Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency Latest News from Aeglea View All May 05, 2022 Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market May 05, 2022 Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates Apr 12, 2022 Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency Make a Difference Join Our Team CompanyAboutLeadershipPartneringContact FocusEnzyme TherapeuticsRare Metabolic DiseasePublications ProgramsPipelinePegzilarginaseAGLE-177Research ProgramsClinical Trials CareersJob OpeningsLife at Aeglea Investors & MediaCompany OverviewPress ReleasesEvents & PresentationsStock InformationFinancialsCorporate GovernanceResources Patients & FamiliesOverviewArginase 1 DeficiencyHomocystinuriaDiet & NutritionClinical Trials FAQs © 2022 Aeglea BioTherapeutics. Privacy PolicyTerms of UsePurchase TermsCOVID-19 Statement This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page. Accept Welcome About ARG1-D Diagnosing ARG1-D Managing ARG1-D Patient Advocacy Connect